Reminder for ImmunityBio Securities Class Action
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 13 2026
0mins
Source: Globenewswire
- Class Action Notification: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, that they must apply to be lead plaintiff by May 26, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will not incur any upfront costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, resulting in investor losses when the true information was revealed, highlighting transparency issues within the company.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and experience in handling such cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.740
Low
5.00
Averages
7.33
High
9.00
Current: 7.740
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder for ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 24, 2026, to apply as lead plaintiffs by May 26, 2026, to participate in the class action, as those who do not will not be represented.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more victims to seek compensation.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, resulting in investor losses when the truth emerged, potentially impacting the company's reputation and future financing capabilities.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, ranked first by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in this field.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading efficacy claims made by its Chief Scientific Officer regarding its lead biologic product, Anktiva, during a podcast, with the class period spanning from January 19 to March 24, 2026, potentially impacting investors significantly.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that promotional materials for Anktiva in a podcast and TV ad were false or misleading, resulting in a 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization.
- Investor Rights: Hagens Berman is investigating whether ImmunityBio intentionally misled investors and is urging affected investors to submit their losses while also encouraging witnesses to assist in the ongoing investigation, highlighting the firm's commitment to protecting shareholder rights.
- Public Health Impact: The FDA emphasized that ImmunityBio's promotional claims misrepresented Anktiva's benefits and failed to provide complete information regarding its FDA-approved indications, raising serious public health concerns about misleading patients regarding treatment expectations.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against ImmunityBio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 19 and March 24, 2026.
- False Statement Allegations: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva drug, resulting in investor losses when the truth emerged, highlighting significant deficiencies in the company's disclosure practices.
- Investor Rights Protection: The Schall Law Firm encourages affected investors to contact them before May 26, 2026, to participate in the lawsuit and discuss their rights, demonstrating a commitment to safeguarding investor interests.
- Lawsuit Status Explanation: The class action has not yet been certified, meaning investors are not represented by an attorney during this period, underscoring the importance of participating in the lawsuit to ensure their rights are protected.
See More
ImmunityBio Faces Class Action Lawsuit for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ImmunityBio, seeking damages for investors who purchased securities between January 19 and March 24, 2026, reflecting strong investor response to potential fraud allegations.
- False Statement Allegations: The complaint alleges that ImmunityBio's executive Soon-Shion materially overstated Anktiva's capabilities, leading to materially false and misleading statements about the company's business and prospects, which could result in significant losses for investors.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by May 26, 2026, to share in any potential recovery from the lawsuit, demonstrating the legal team's commitment to protecting investor rights.
- No-Risk Legal Services: Bronstein, Gewirtz & Grossman, LLC offers contingency fee-based legal services, charging only if they successfully recover funds, highlighting the firm's strong focus on investor interests and accountability.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, that the deadline to apply as lead plaintiff is May 26, 2026, allowing potential compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that executives made false statements during the class period, resulting in investor losses once the true information was revealed, highlighting significant deficiencies in the company's transparency and compliance.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and secured over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling such cases.
- Investor Selection Advice: Investors are advised to choose law firms with proven success rather than those acting merely as intermediaries, ensuring they receive the best representation and support in litigation.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading efficacy claims made by Chairman Soon-Shiong regarding Anktiva, which resulted in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Lawsuit Context: The class action lawsuit seeks to represent investors who purchased ImmunityBio securities between January 19 and March 24, 2026, alleging violations of federal securities laws, with Hagens Berman investigating claims and urging affected investors to come forward.
- Promotional Material Issues: The FDA criticized ImmunityBio's promotional materials for misleading the public by suggesting Anktiva could cure all cancers, while it is only approved for non-muscle invasive bladder cancer, emphasizing the lack of data supporting such efficacy claims, which poses serious public health risks.
- Investor Alert: Hagens Berman encourages investors to report their losses and warns knowledgeable individuals to consider assisting in the investigation, indicating significant challenges for the company regarding transparency and compliance, which could lead to broader legal and financial repercussions.
See More
Reminder for ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 24, 2026, to apply as lead plaintiffs by May 26, 2026, to participate in the class action, as those who do not will not be represented.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more victims to seek compensation.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, resulting in investor losses when the truth emerged, potentially impacting the company's reputation and future financing capabilities.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, ranked first by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in this field.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading efficacy claims made by its Chief Scientific Officer regarding its lead biologic product, Anktiva, during a podcast, with the class period spanning from January 19 to March 24, 2026, potentially impacting investors significantly.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that promotional materials for Anktiva in a podcast and TV ad were false or misleading, resulting in a 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization.
- Investor Rights: Hagens Berman is investigating whether ImmunityBio intentionally misled investors and is urging affected investors to submit their losses while also encouraging witnesses to assist in the ongoing investigation, highlighting the firm's commitment to protecting shareholder rights.
- Public Health Impact: The FDA emphasized that ImmunityBio's promotional claims misrepresented Anktiva's benefits and failed to provide complete information regarding its FDA-approved indications, raising serious public health concerns about misleading patients regarding treatment expectations.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against ImmunityBio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 19 and March 24, 2026.
- False Statement Allegations: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva drug, resulting in investor losses when the truth emerged, highlighting significant deficiencies in the company's disclosure practices.
- Investor Rights Protection: The Schall Law Firm encourages affected investors to contact them before May 26, 2026, to participate in the lawsuit and discuss their rights, demonstrating a commitment to safeguarding investor interests.
- Lawsuit Status Explanation: The class action has not yet been certified, meaning investors are not represented by an attorney during this period, underscoring the importance of participating in the lawsuit to ensure their rights are protected.
See More
ImmunityBio Faces Class Action Lawsuit for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ImmunityBio, seeking damages for investors who purchased securities between January 19 and March 24, 2026, reflecting strong investor response to potential fraud allegations.
- False Statement Allegations: The complaint alleges that ImmunityBio's executive Soon-Shion materially overstated Anktiva's capabilities, leading to materially false and misleading statements about the company's business and prospects, which could result in significant losses for investors.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by May 26, 2026, to share in any potential recovery from the lawsuit, demonstrating the legal team's commitment to protecting investor rights.
- No-Risk Legal Services: Bronstein, Gewirtz & Grossman, LLC offers contingency fee-based legal services, charging only if they successfully recover funds, highlighting the firm's strong focus on investor interests and accountability.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, that the deadline to apply as lead plaintiff is May 26, 2026, allowing potential compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that executives made false statements during the class period, resulting in investor losses once the true information was revealed, highlighting significant deficiencies in the company's transparency and compliance.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and secured over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling such cases.
- Investor Selection Advice: Investors are advised to choose law firms with proven success rather than those acting merely as intermediaries, ensuring they receive the best representation and support in litigation.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading efficacy claims made by Chairman Soon-Shiong regarding Anktiva, which resulted in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Lawsuit Context: The class action lawsuit seeks to represent investors who purchased ImmunityBio securities between January 19 and March 24, 2026, alleging violations of federal securities laws, with Hagens Berman investigating claims and urging affected investors to come forward.
- Promotional Material Issues: The FDA criticized ImmunityBio's promotional materials for misleading the public by suggesting Anktiva could cure all cancers, while it is only approved for non-muscle invasive bladder cancer, emphasizing the lack of data supporting such efficacy claims, which poses serious public health risks.
- Investor Alert: Hagens Berman encourages investors to report their losses and warns knowledgeable individuals to consider assisting in the investigation, indicating significant challenges for the company regarding transparency and compliance, which could lead to broader legal and financial repercussions.
See More
